KathleenMDunganMD

Endocrinology • Columbus, OH

Diabetes, Lipid Metabolism

Professor of Medicine, Ohio State University

Join to view full profile

Dr. Dungan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dungan's full profile

Already have an account?

Office
543 Taylor Ave
2nd Floor
Columbus, OH 43203
Phone+1 614-685-3333

Fax+1 614-366-0345

Summary

Dr. Kathleen Dungan is an endocrinologist in Columbus, OH and is affiliated with multiple hospitals in the area, including Ohio State University Wexner Medical Center, James Cancer Hospital and Solove Research Institute, and Chillicothe Veterans Affairs Medical Center. She received her medical degree from Ohio State University College of Medicine and has been in practice 16 years. She specializes in diabetes and lipid metabolism.

Education & Training

University of North Carolina HospitalsFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
University of North Carolina HospitalsResidency, Internal Medicine, 2001 - 2004
Ohio State University College of MedicineClass of 2001

Certifications & Licensure

OH State Medical License 2006 - 2025
NC State Medical License 2001 - 2006
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir Start of enrollment: 2008 Jul 01
Completed
Phase 4
Intensive Glycemic Control for Congestive Heart Failure Exacerbation Start of enrollment: 2009 Jan 01
Completed
Phase 2
Glycemic Control and Variability for Congestive Heart Failure Exacerbation Start of enrollment: 2009 Jan 01
Completed
Phase 1, Phase 2
Prandial Insulin Dosing in Hospitalized Patients Start of enrollment: 2010 Jun 01
Completed
Phase 4
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes Start of enrollment: 2011 Jul 01
Completed
Phase 4
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes Start of enrollment: 2013 Aug 01
Completed
Phase 4
Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery Start of enrollment: 2014 Jan 01
Terminated
Phase 4
Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Mar 01
Terminated
Phase 2
Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin Start of enrollment: 2018 May 01
Terminated
Not Applicable
Join now to see all

Publications & Presentations

PubMed

89 citations
A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.
David C Klonoff, Jing Wang, David Rodbard, Michael A Kohn, Chengdong Li
Journal of Diabetes Science and Technology. 2023-09-01
999 citations
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled t...
Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, Ralph B. D'Agostino, Christopher B. Granger
Lancet. 2018-10-27
101 citations
Endothelial Dysfunction: Associations with Exposure to Ambient Fine Particles in Diabetic Individuals
Alexandra Schneider, Lucas M. Neas, Margaret C. Herbst, Martin Case, Ronald Williams
Environmental Health Perspectives. 2008-12-01

Lectures

A Comparison of Continuous Intravenous Insulin and Subcutaneous Insulin among Patients with Type 2 Diabetes and Congestive Heart Failure Exacerbation
Columbus, OH - 6/16/2014

Press Mentions

Ozempic and Wegovy May Aid Anti-Cancer ‘Natural Killer’ CellsMay 16th, 2023
Diabetes Drugs May Help Reduce Risk of Cardiovascular Events in Older AdultsMay 8th, 2023
Type 2 Diabetes Drug Mounjaro Leads to 16 Percent Weight Loss in New Trial for Treatment of Overweight or ObesityApril 28th, 2023
Join now to see all

Grant Support

Intensive Glycemic Control For Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
Glycemic Control And Variability In Congestive Heart Failure ExacerbationNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2009